Investors in Danaher� (NYSE: DHR ) saw the company deliver a disappointing set of second-quarter results that caused the stock to drop notably. In fact, as of today, it's pretty much flat on a six-month basis. In truth, the results weren't that bad: The midpoint of full-year generally accepted accounting principles earnings per share guidance was actually raised by a couple cents as management narrowed its guidance to $3.67-$3.72 from $3.60-$3.75.
However, the market obviously expected more, and certain elements of the company's performance surprised on the downside. Danaher reports out of five segments: industrial technologies, environmental (mainly water quality), dental, life sciences and diagnostics, and test and measurement. This kind of diversification normally means that the company is broadly exposed to the industrial economy, and management's commentary certainly reflected a moderately growing environment. With that said, here are five things management wants you to know about the quarter.
Best Solar Companies To Invest In 2015: Kiwibox.com Inc (KIWB)
Kiwibox.Com, Inc. (Kiwibox), incorporated on April 19, 1988, is an early stage company. The Company owns and operates Kiwibox.com, which is a social networking Website. The Company has equipped the Website with the advertising features, which enable sponsors to self-direct their message to specific target audiences based on gender, age, geographic region, education, and interests. As of December 31, 2011, the Company generated the majority of its revenue from advertising/sponsorships. On September 30, 2011 Kiwibox.com acquired 100% interests in the social network, KWICK!! Community GmbH & Co. KG, and interest of its general partner, Kwick!! Community Beteiligungs GMBH. On March 7, 2011 the Company acquired Pixunity.DE a German photo book community.
Kiwibox.com has developed a monitoring model. The Kiwibox.com platform is equipped with technology features, which includes the private sphere configuration of users, contact blocs, anti-spam protection and intelligent self-learning user-scoring feature.
The Company competes with Facebook.com, Twitter and MySpace.com.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks Kiwibox.com Inc (OTCMKTS: KIWB), Eyes on The Go Inc (OTCMKTS: AXCG) and Green Endeavors Inc (OTCMKTS: GRNE) were sinking 37.5%, 28.57% and 23.9%, respectively. Moreover, it should be mentioned that all three small cap stocks have been the subject of recent paid promotions or investor relation campaigns which have gotten them mentions in various investment newsletters or investor alerts. So are the promotional or investor relation campaigns over with for these three small caps? Here is a quick look to help you decide:
Kiwibox.com Inc (OTCMKTS: KIWB) Makes an Acquisition in Germany and Reports Surging RegistrationsSmall cap Kiwibox.com Inc owns and operates social networking sites like Kiwibox.com, a site that has over over 14 years experience as social network. On Friday, Kiwibox.com Inc sank 37.5% to $0.005 for a market cap of $3.41 million plus KIWB is down 58.3% over the past year and down 63% over the past five years according to Google Finance.
Top 10 Life Sciences Companies To Buy For 2014: Vanguard Reit Etf (VNQ)
Vanguard REIT ETF (the Fund), formerly known as Vanguard REIT VIPERs, is an exchange-traded share class of Vanguard REIT Index Fund. The Fund seeks to provide a high level of income and moderate long-term capital appreciation by tracking the performance of an index that measures the performance of publicly traded equity real estate investment trusts (REITs). Vanguard REIT ETF employs a passive management or indexing investment approach designed to track the performance of the MSCI US REIT Index (the Index), an index of United States property trusts that covers about two-thirds of the value of the entire United States REIT market.
Vanguard REIT ETF normally invests approximately 98% of assets in stocks issued by equity REITs. The Fund invests in the stocks that make up the Index, and the remaining assets are allocated to cash investments.
Advisors' Opinion:- [By Howard Gold]
In May, I said real estate investment trusts (REITs) ��ave outperformed the S&P 500 for 11 of the last 16 quarters��and so ��'d be inclined to take at least some profits.��That column ran pretty close to REITs' all-time high and the Vanguard REIT Index ETF (VNQ) has lost 11% of its value.
Top 10 Life Sciences Companies To Buy For 2014: OCI Partners LP (OCIP)
OCI Partners LP, incorporated on February 07, 2013, owns and operates an integrated methanol and ammonia production facility that is strategically located on the Texas Gulf Coast near Beaumont. The Company is a methanol producer in the United States with an annual methanol production capacity of approximately 730,000 metric tons and an annual ammonia production capacity of approximately 265,000 metric tons, and it is in the early stages of a debottlenecking project that increases its annual methanol production capacity by 25% to approximately 912,500 metric tons and its annual ammonia production capacity by 15% to approximately 305,000 metric tons.
Both methanol and ammonia are global commodities that are essential building blocks for numerous end-use products. Methanol is a liquid petrochemical that is used in a variety of industrial and energy-related applications. Methanol is used in industrial applications to produce adhesives used in manufacturing wood products, such as plywood, particle board and laminates, resins to treat paper and plastic products, paint and varnish removers, solvents for the textile industry and polyester fibers for clothing and carpeting. Methanol is also used outside of the United States as a direct fuel for automobile engines, as a fuel blended with gasoline and as an octane booster in reformulated gasoline. In the United States, ammonia is primarily used as a feedstock to produce nitrogen fertilizers, such as urea and ammonium sulfate, and is also directly applied to soil as a fertilizer. In addition, ammonia is widely used in industrial applications, particularly in the Texas Gulf Coast market, including in the production of plastics, synthetic fibers, resins and numerous other chemical compounds.
Advisors' Opinion:- [By Robert Rapier]
OCI Partners (Nasdaq: OCIP) owns and operates OCI Beaumont, an integrated methanol and ammonia production facility on the Texas Gulf Coast. OCI Beaumont has a methanol production capacity of 730,000 metric tons (MT) per year and an ammonia production capacity of 265,000 MT per year. The facility is in the middle of a debottlenecking project that will increase its annual methanol production capacity by 25 percent and its annual ammonia production capacity by 15 percent.
- [By Robert Rapier]
Rounding out the bottom five were�OCI Partners�(NYSE: OCIP), a methanol and ammonia producer (-24 percent YTD),�Natural Resource Partners�(NYSE: NRP), another coal producer (-19 percent), and�Eagle Rock Energy Partners�(NASDAQ: EROC), an oil and gas production partnership (-17 percent).
- [By Paul Ausick]
Stocks on the Move: Potbelly Corp. (NASDAQ: PBPB) is up 119.1% at $30.68 after a blistering IPO at $14 a share. OCI Partners LP (NYSE: OCIP) is up 5.6% at $19.01 after an IPO at $18.00 a share. Cherry Hill Mortgage Investment Corp. (NYSE: CHMI) is down 7.6% at $18.48 following its IPO on Friday morning. Discovery Laboratories Inc. (NASDAQ: DSCO) is up 37.1% at $2.70 following approval of updated specifications for a drug to prevent respiratory distress in premature infants. Forest Oil Corp. (NYSE: FST) is down 9.7% at $5.74 following the sale of $1 billion worth of assets in the Texas panhandle.
Top 10 Life Sciences Companies To Buy For 2014: Flexpoint Sensor Systems Inc (FLXT)
Flexpoint Sensor Systems, Inc.(Flexpoint), incorporated on June 11, 1992, is a development stage company. The Company is principally engaged in designing, engineering and manufacturing bend sensor technology and products using its patented Bend Sensor technology. Flexpoint manufactures, and has jointly developed, six products that are being sold and supplied to customers. Flexpoint owns nine patents, including patents on specific devices that use the Bend Sensor. The Company works with various Tier 1 (major) automotive suppliers on a variety of products that are in various stages of development and implementation.
Bend Sensor Technology
Flexpoint owns the patent rights to the Company's Bend Sensor technology through Sensitron, Inc. (Sensitron), a wholly owned subsidiary of the Company. The Bend Sensor is a potentiometer bend sensor product consisting of a coated substrate, such as plastic, that changes electrical conductivity as it is bent in a consistent manner. Electronic systems can connect to this sensor and measure in detail the amount of bending or movement that occurs in a predictable manner. A potentiometer functions through the means of metal contacts swiping or rubbing across a resistive element. Flexpoin�� Bend Sensor potentiometer is a single layer with no mechanical assembly that makes it more reliable and smaller, and lighter in weight.
Automotive Products
Flexpoint has developed comfort seat for automobiles utilizing its patented Bend Sensortechnology and is working with Tier 1 suppliers on development of the seat and various seat related controls. Through a joint development arrangement with a Tier1supplier Flexpoint developed and delivered prototypes of the seat. Automobile manufacture has partnered with a Tier 1 supplier and is in the final stages of evaluating Flexpoint�� patented horn switch to replace their existing technology. The automobile manufacturer is also evaluating the use of the Bend Sensor as a switch to open rear! doors of SUV's and as a seat belt reminder (SBR). While working with various Tier 1 automotive suppliers the Company has developed and tested a SBR sensor that alerts the occupant of an automobile to fasten his/her seatbelt.
Flexpoint is working with multiple manufacturers to replace existing devices in the marketplace with a system superior in performance. Four separate and independent automotive suppliers and OEMs tested the Bend Sensor device for use in pedestrian impact detection device. The tests proved that the Bend Sensor device was able to detect impact with a human leg and in the event of an accident and trigger the desired safety response. Flexpoint has also developed a crash sensor, which is a series of sensors mounted in strategic places on the side and door panels of an automobile to detect an impact, as well as the speed, direction and force of the impact. This allows an onboard computer to deploy side air bags where needed. Using the same concept as the Company's automotive seat belt reminder (SBR), this device monitors cinema theater's paying customers and identifies available seats. Flexpoint has supplied a theater management firm with several prototype sensors, which have undergone extensive testing for this application.
As of December 31, 2012, Flexpoint developed and produced 20 prototype medical beds that assist in the management of bed sores. Using the Bend Sensor technology and accompanying electronics the bed is able to determine the position of the person in the bed and how they are moved. The Company has developed a vibration sensor, a rupture disc/bursting disc utilizing the Bend Sensor as the detection/alarm element of a rupture disc device, an infant bed cover using its patented sensors that is used to monitor infants in the prevention of sudden infant death syndrome (SIDS), toys and video gaming devices, and sports applications.
Advisors' Opinion:- [By CRWE]
Today, FLXT has shed (-6.25%) down -0.0060 at $.0900 with 19,500 shares in play thus far (ref. google finance Delayed: 11:10AM EDT September 25, 2013).
Flexpoint Sensor Systems, Inc. previously reported they expect to complete both Phase Two and Phase Three of development of the colonoscope application during the remainder of 2013. The company will receive milestone cash payments for each stage of the development process.
Top 10 Life Sciences Companies To Buy For 2014: Juno Therapeutics Inc (JUNO)
Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.
To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.
CD19-Directed Product Candidates
The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.
JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.
JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.
Additional Product Candidates
The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.
The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.
The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.
Advisors' Opinion:- [By John Udovich]
Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.
Top 10 Life Sciences Companies To Buy For 2014: Yanzhou Coal Mining Company Limited(YZC)
Yanzhou Coal Mining Company Limited engages in the underground mining, preparation, and sale of coal. It involves in manufacturing, washing, processing, and selling steam coal used in the electricity power sector; and metallurgical coal used with coking coal in the process of pulverized coal injection, as well as operates six coal mines. The company also engages in the provision of railway transportation services; production and sale of coal chemicals, primarily methanol; and generation of electricity and heat. In addition, it involves in the manufacture and sale of mining machinery and engine products; and development of integrated coal technology. Further, the company engages in the transportation via rivers and lakes; sale of construction materials; and trading and processing of mining machinery. It has operations primarily in China, Japan, South Korea, and Australia. The company was founded in 1973 and is based in Zoucheng, the People's Republic of China. Yanzhou Coal Mining Company Limited is a subsidiary of Yankuang Group Corporation Limited.
Advisors' Opinion:- [By MarketWatch]
Treasurer Joe Hockey said Yanzhou Coal Mining Co. (YZC) no longer needed to meet a Dec. 31 deadline for reducing its stake in Yancoal Australia Ltd. (YAL.AU) below 70%, citing the downturn in global coal prices. Yanzhou, which owns 78% of Yancoal Australia, had made the commitment in 2009 to complete its 3.5 billion Australian dollar (US$3.2 billion) takeover of Felix Resources Ltd.
- [By Belinda Cao]
Yanzhou Coal Mining Co. (YZC), China�� fourth-largest coal producer, lost 3.6 percent last week to $10.33. The company posted its eighth weekly slump, the longest stretch of declines since August 1998. Bank of America Corp. cut the stock to the equivalent of sell from neutral May 3.
- [By Roberto Pedone]
Yanzhou Coal Mining (YZC) engages in the underground coal mining, as well as preparation, processing, sale and railway transportation of coal. This stock closed up 7.6% to $7.31 in Thursday's trading session.
Thursday's Range: $7.14-$7.31
52-Week Range: $6.68-$18.57
Thursday's Volume: 391,000
Three-Month Average Volume: 370,383From a technical perspective, YZC bounced sharply higher here right off some near-term support at $6.77 with above-average volume. This stock has been downtrending badly for the last six months, with shares plunging from its high of over $14 to its recent low of $6.68. During that move, shares of YZC have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of YZC have recently formed a double bottom chart pattern at $6.68 to $6.77. This stock now looks ready to reverse that downtrend and possibly trigger a near-term breakout trade. That trade will hit if YZC manages to take out some near-term overhead resistance levels at $7.76 to $8 with high volume.
Traders should now look for long-biased trades in YZC as long as it's trending above its recent low of $6.77 and then once it sustains a move or close above those breakout levels with volume that hits near or above 370,383 shares. If that breakout triggers soon, then YZC will set up to re-test or possibly take out its next major overhead resistance levels at $9 to $10. Any high-volume move above those levels will then give YZC a chance to tag its next major overhead resistance levels at $10.67 to $11.11.
Top 10 Life Sciences Companies To Buy For 2014: Silicon Laboratories Inc.(SLAB)
Silicon Laboratories Inc., a fabless semiconductor company, designs, develops, and markets analog-intensive and mixed-signal integrated circuits (ICs). The company offers broad-based products, which include microcontrollers, clocks and oscillators, wireless transceivers, digital isolators and related products, and human interface sensors and controllers; broadcast products comprising radio receivers and transmitters, and video tuners and demodulators; and access products consisting of embedded modems, subscriber line interface circuits, Voice over IP (VoIP) products, and power over Ethernet devices, as well as DSL analog front end ICs and IRDA devices. It provides ICs for use in various electronic applications, such as portable devices, AM/FM radios, and other consumer electronics, as well as networking, test and measurement, industrial monitoring and control, and customer premises equipment. The company markets its products through direct sales force, and through a networ k of independent sales representatives and distributors in the United States, Taiwan, China, South Korea, Japan, and internationally. Silicon Laboratories Inc. was founded in 1996 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 15.32 percent, and Informatica (NASDAQ: INFA), off 11.91 percent.
- [By Rich Smith]
Austin, Texas-based Silicon Laboratories (NASDAQ: SLAB ) , which chose a new chief financial officer last month, has now found him a bit of extra work to do.
- [By MONEYMORNING.COM]
XSD holds such big-cap names as Texas Instruments Inc. (Nasdaq: TXN) and Intel Corp. (Nasdaq: INTC). It also owns Atmel Corp. (Nasdaq: ATML), which has a market cap of less than $4 billion, and Silicon Laboratories Inc. (Nasdaq: SLAB), with a market cap of $2 billion.
- [By Garrett Cook]
In trading on Friday, technology shares were relative laggards, down on the day by about 0.80 percent. Top decliners in the sector included Silicon Laboratories (NASDAQ: SLAB), down 13.7 percent, and Informatica (NASDAQ: INFA), off 13.4 percent.
No comments:
Post a Comment